Natera, Inc. (NASDAQ: NTRA) Stock Competitors & Peer Comparison
See NTRA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NTRA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NTRA | $403.35 | +0.49% | 58.2B | -306.02 | -$1.32 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.67% |
| TMO | $682.02 | +0.81% | 249.2B | 29.10 | $23.16 | +0.27% |
| DHR | $232.53 | +1.21% | 162B | 28.88 | $7.98 | +0.67% |
| A | $175.99 | +1.20% | 48.8B | 29.78 | $5.81 | +0.59% |
| IQV | $279.96 | +0.59% | 46B | 23.03 | $12.13 | N/A |
| WAT | $460.37 | +1.05% | 44.5B | 33.16 | $13.68 | N/A |
| IDXX | $565.94 | -0.14% | 44.1B | 39.41 | $14.22 | N/A |
| ILMN | $270.08 | +0.25% | 40.7B | 53.56 | $5.03 | N/A |
| MTD | $1,672.74 | -0.71% | 33.4B | 38.35 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
NTRA vs DHR-PB Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NTRA's ROE is -0.12%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, NTRA is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
NTRA vs TMO Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, TMO has a market cap of 249.2B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while TMO trades at $682.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas TMO's P/E ratio is 29.10. In terms of profitability, NTRA's ROE is -0.12%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NTRA is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
NTRA vs DHR Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, DHR has a market cap of 162B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while DHR trades at $232.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas DHR's P/E ratio is 28.88. In terms of profitability, NTRA's ROE is -0.12%, compared to DHR's ROE of +0.08%. Regarding short-term risk, NTRA is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check DHR's competition here
Agilent Technologies, Inc. (NYSE: A)
NTRA vs A Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while A trades at $175.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas A's P/E ratio is 29.78. In terms of profitability, NTRA's ROE is -0.12%, compared to A's ROE of +0.20%. Regarding short-term risk, NTRA is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
NTRA vs IQV Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, IQV has a market cap of 46B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while IQV trades at $279.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas IQV's P/E ratio is 23.03. In terms of profitability, NTRA's ROE is -0.12%, compared to IQV's ROE of +0.22%. Regarding short-term risk, NTRA is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check IQV's competition here
Waters Corporation (NYSE: WAT)
NTRA vs WAT Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, WAT has a market cap of 44.5B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while WAT trades at $460.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas WAT's P/E ratio is 33.16. In terms of profitability, NTRA's ROE is -0.12%, compared to WAT's ROE of +0.02%. Regarding short-term risk, NTRA is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
NTRA vs IDXX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while IDXX trades at $565.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas IDXX's P/E ratio is 39.41. In terms of profitability, NTRA's ROE is -0.12%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, NTRA is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
NTRA vs ILMN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ILMN has a market cap of 40.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ILMN trades at $270.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ILMN's P/E ratio is 53.56. In terms of profitability, NTRA's ROE is -0.12%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, NTRA is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
NTRA vs MTD Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MTD has a market cap of 33.4B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MTD trades at $1,672.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MTD's P/E ratio is 38.35. In terms of profitability, NTRA's ROE is -0.12%, compared to MTD's ROE of -12.00%. Regarding short-term risk, NTRA is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
NTRA vs DGX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, DGX has a market cap of 26.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while DGX trades at $241.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas DGX's P/E ratio is 23.85. In terms of profitability, NTRA's ROE is -0.12%, compared to DGX's ROE of +0.15%. Regarding short-term risk, NTRA is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
NTRA vs LH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, LH has a market cap of 26.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while LH trades at $330.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas LH's P/E ratio is 19.53. In terms of profitability, NTRA's ROE is -0.12%, compared to LH's ROE of +0.12%. Regarding short-term risk, NTRA is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
NTRA vs GH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, GH has a market cap of 22.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while GH trades at $170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas GH's P/E ratio is -48.45. In terms of profitability, NTRA's ROE is -0.12%, compared to GH's ROE of +2.11%. Regarding short-term risk, NTRA is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
NTRA vs EXAS Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas EXAS's P/E ratio is -95.37. In terms of profitability, NTRA's ROE is -0.12%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, NTRA is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
NTRA vs MEDP Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MEDP has a market cap of 18.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MEDP trades at $666.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MEDP's P/E ratio is 39.23. In terms of profitability, NTRA's ROE is -0.12%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, NTRA is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
NTRA vs RVTY Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, RVTY has a market cap of 17.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while RVTY trades at $161.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas RVTY's P/E ratio is 29.67. In terms of profitability, NTRA's ROE is -0.12%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, NTRA is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
NTRA vs ILMNV Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ILMNV's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to ILMNV's ROE of N/A. Regarding short-term risk, NTRA is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
NTRA vs CRL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CRL has a market cap of 16.6B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CRL trades at $354.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CRL's P/E ratio is 34.87. In terms of profitability, NTRA's ROE is -0.12%, compared to CRL's ROE of -0.08%. Regarding short-term risk, NTRA is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CRL's competition here
PerkinElmer, Inc. (NYSE: PKI)
NTRA vs PKI Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas PKI's P/E ratio is 41.45. In terms of profitability, NTRA's ROE is -0.12%, compared to PKI's ROE of +0.03%. Regarding short-term risk, NTRA is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
NTRA vs ICLR Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ICLR has a market cap of 14.3B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ICLR trades at $184.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ICLR's P/E ratio is 15.11. In terms of profitability, NTRA's ROE is -0.12%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, NTRA is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
NTRA vs QGEN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while QGEN trades at $50.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas QGEN's P/E ratio is 20.82. In terms of profitability, NTRA's ROE is -0.12%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, NTRA is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
NTRA vs GRAL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, GRAL has a market cap of 5.9B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while GRAL trades at $136.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas GRAL's P/E ratio is -13.59. In terms of profitability, NTRA's ROE is -0.12%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, NTRA is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
NTRA vs RDNT Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while RDNT trades at $71.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas RDNT's P/E ratio is 152.91. In terms of profitability, NTRA's ROE is -0.12%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, NTRA is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
NTRA vs SHC Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while SHC trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas SHC's P/E ratio is 18.85. In terms of profitability, NTRA's ROE is -0.12%, compared to SHC's ROE of +0.27%. Regarding short-term risk, NTRA is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
NTRA vs BLLN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BLLN has a market cap of 5.1B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BLLN trades at $109.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BLLN's P/E ratio is 153.96. In terms of profitability, NTRA's ROE is -0.12%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, NTRA is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
NTRA vs SYNH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NTRA's ROE is -0.12%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NTRA is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
NTRA vs VCYT Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while VCYT trades at $48.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas VCYT's P/E ratio is 23.97. In terms of profitability, NTRA's ROE is -0.12%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, NTRA is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
NTRA vs CDNA Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CDNA trades at $69.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CDNA's P/E ratio is 82.39. In terms of profitability, NTRA's ROE is -0.12%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, NTRA is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
NTRA vs OLK Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas OLK's P/E ratio is -96.59. In terms of profitability, NTRA's ROE is -0.12%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NTRA is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
NTRA vs NEO Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while NEO trades at $16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas NEO's P/E ratio is 127.62. In terms of profitability, NTRA's ROE is -0.12%, compared to NEO's ROE of -0.06%. Regarding short-term risk, NTRA is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check NEO's competition here
Personalis, Inc. (NASDAQ: PSNL)
NTRA vs PSNL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while PSNL trades at $15.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas PSNL's P/E ratio is -14.52. In terms of profitability, NTRA's ROE is -0.12%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, NTRA is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check PSNL's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
NTRA vs WGS Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, WGS has a market cap of 1.7B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while WGS trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas WGS's P/E ratio is 155.97. In terms of profitability, NTRA's ROE is -0.12%, compared to WGS's ROE of -0.39%. Regarding short-term risk, NTRA is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check WGS's competition here
OPKO Health, Inc. (NASDAQ: OPK)
NTRA vs OPK Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while OPK trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas OPK's P/E ratio is -18.33. In terms of profitability, NTRA's ROE is -0.12%, compared to OPK's ROE of -0.06%. Regarding short-term risk, NTRA is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
NTRA vs CSTL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CSTL trades at $33.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CSTL's P/E ratio is -50.12. In terms of profitability, NTRA's ROE is -0.12%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, NTRA is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
NTRA vs GRALV Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas GRALV's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to GRALV's ROE of N/A. Regarding short-term risk, NTRA is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
NTRA vs MYGN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MYGN has a market cap of 557.6M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MYGN trades at $5.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MYGN's P/E ratio is -44.85. In terms of profitability, NTRA's ROE is -0.12%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, NTRA is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
NTRA vs FLGT Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, FLGT has a market cap of 553.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while FLGT trades at $20.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas FLGT's P/E ratio is 2010.00. In terms of profitability, NTRA's ROE is -0.12%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, NTRA is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
NTRA vs CO Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CO's P/E ratio is 5.06. In terms of profitability, NTRA's ROE is -0.12%, compared to CO's ROE of +0.11%. Regarding short-term risk, NTRA is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
NTRA vs FLDM Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NTRA's ROE is -0.12%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, NTRA is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
NTRA vs XGN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, XGN has a market cap of 176.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while XGN trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas XGN's P/E ratio is -8.98. In terms of profitability, NTRA's ROE is -0.12%, compared to XGN's ROE of -1.22%. Regarding short-term risk, NTRA is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
NTRA vs BDSX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BDSX has a market cap of 172.4M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BDSX trades at $21.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BDSX's P/E ratio is -6.68. In terms of profitability, NTRA's ROE is -0.12%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, NTRA is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
NTRA vs GTH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas GTH's P/E ratio is -1.11. In terms of profitability, NTRA's ROE is -0.12%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NTRA is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
NTRA vs GENE Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas GENE's P/E ratio is -38.25. In terms of profitability, NTRA's ROE is -0.12%, compared to GENE's ROE of -1.85%. Regarding short-term risk, NTRA is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
NTRA vs FRNM Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, FRNM has a market cap of 104.2M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while FRNM trades at $12.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas FRNM's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to FRNM's ROE of N/A. Regarding short-term risk, NTRA is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
NTRA vs IMDX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, IMDX has a market cap of 92.6M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while IMDX trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas IMDX's P/E ratio is -1.90. In terms of profitability, NTRA's ROE is -0.12%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, NTRA is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
NTRA vs PRPO Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, PRPO has a market cap of 37.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while PRPO trades at $19.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas PRPO's P/E ratio is -31.92. In terms of profitability, NTRA's ROE is -0.12%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, NTRA is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
NTRA vs AKU Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas AKU's P/E ratio is -0.13. In terms of profitability, NTRA's ROE is -0.12%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NTRA is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
NTRA vs QUCY Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, QUCY has a market cap of 23M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while QUCY trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas QUCY's P/E ratio is -0.05. In terms of profitability, NTRA's ROE is -0.12%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, NTRA is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check QUCY's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
NTRA vs BIAF Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BIAF trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BIAF's P/E ratio is -0.33. In terms of profitability, NTRA's ROE is -0.12%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, NTRA is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BIAF's competition here
MDxHealth S.A. (NASDAQ: MDXH)
NTRA vs MDXH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MDXH has a market cap of 17.5M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MDXH trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MDXH's P/E ratio is -0.25. In terms of profitability, NTRA's ROE is -0.12%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, NTRA is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
NTRA vs CEMI Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NTRA's ROE is -0.12%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NTRA is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
NTRA vs ENZ Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NTRA's ROE is -0.12%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, NTRA is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
NTRA vs PMD Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas PMD's P/E ratio is -5.24. In terms of profitability, NTRA's ROE is -0.12%, compared to PMD's ROE of -0.32%. Regarding short-term risk, NTRA is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
NTRA vs ME Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ME's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.12%, compared to ME's ROE of -3.47%. Regarding short-term risk, NTRA is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
NTRA vs MYNZ Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, NTRA's ROE is -0.12%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, NTRA is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
NTRA vs BNR Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BNR has a market cap of 12.5M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BNR trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BNR's P/E ratio is -13.59. In terms of profitability, NTRA's ROE is -0.12%, compared to BNR's ROE of -0.13%. Regarding short-term risk, NTRA is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
NTRA vs CHEK Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CHEK's P/E ratio is -0.43. In terms of profitability, NTRA's ROE is -0.12%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, NTRA is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
NTRA vs CNTG Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NTRA's ROE is -0.12%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NTRA is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
NTRA vs APDN Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas APDN's P/E ratio is -0.10. In terms of profitability, NTRA's ROE is -0.12%, compared to APDN's ROE of -7.23%. Regarding short-term risk, NTRA is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
NTRA vs NDRA Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while NDRA trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas NDRA's P/E ratio is -0.70. In terms of profitability, NTRA's ROE is -0.12%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, NTRA is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
NTRA vs BIAFW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BIAFW has a market cap of 5.7M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BIAFW's P/E ratio is 0.61. In terms of profitability, NTRA's ROE is -0.12%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, NTRA is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
NTRA vs NVTA Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas NVTA's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.12%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, NTRA is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check NVTA's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
NTRA vs ADVB Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ADVB trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ADVB's P/E ratio is -28.82. In terms of profitability, NTRA's ROE is -0.12%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, NTRA is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check ADVB's competition here
LumiraDx Limited (NASDAQ: LMDX)
NTRA vs LMDX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NTRA's ROE is -0.12%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NTRA is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
NTRA vs LMDXW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.12%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NTRA is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
NTRA vs DMTK Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NTRA's ROE is -0.12%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, NTRA is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
NTRA vs NOTV Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas NOTV's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.12%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, NTRA is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
NTRA vs SQL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas SQL's P/E ratio is -0.40. In terms of profitability, NTRA's ROE is -0.12%, compared to SQL's ROE of -30.46%. Regarding short-term risk, NTRA is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
NTRA vs AWH Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas AWH's P/E ratio is -0.09. In terms of profitability, NTRA's ROE is -0.12%, compared to AWH's ROE of +1.62%. Regarding short-term risk, NTRA is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
NTRA vs ISPC Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while ISPC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas ISPC's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.12%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, NTRA is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
NTRA vs HTGM Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NTRA's ROE is -0.12%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NTRA is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
NTRA vs BIOC Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NTRA's ROE is -0.12%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NTRA is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
NTRA vs SQLLW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.12%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, NTRA is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
NTRA vs WGSWW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, NTRA's ROE is -0.12%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, NTRA is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check WGSWW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
NTRA vs CHEKZ Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, NTRA is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check CHEKZ's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
NTRA vs BNGOW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas BNGOW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, NTRA is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
NTRA vs DHR-PA Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NTRA's ROE is -0.12%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, NTRA is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
NTRA vs MEUSW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, NTRA is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
NTRA vs NDRAW Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas NDRAW's P/E ratio is N/A. In terms of profitability, NTRA's ROE is -0.12%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, NTRA is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check NDRAW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
NTRA vs OCDX Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NTRA's ROE is -0.12%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NTRA is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for NTRA.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
NTRA vs PRXL Comparison October 2026
Natera, Inc. (NASDAQ: NTRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTRA stands at 58.2B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, NTRA is priced at $403.35 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTRA currently has a P/E ratio of -306.02, whereas PRXL's P/E ratio is 42.97. In terms of profitability, NTRA's ROE is -0.12%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, NTRA is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for NTRA.Check PRXL's competition here